{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-014601","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.867775+00:00","generated_at":"2026-05-27T02:48:53.476520+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tivic Health shareholders approve reverse stock split authorization (1:2 to 1:30)","bullets":["Reverse split ratio range authorized: 1-for-2 to 1-for-30, at board discretion within 12 months.","Proposal passed with 3,028,943 votes for, 243,254 against, 33,240 abstentions.","Quorum was 34.9% (3,305,437 of 9,467,327 outstanding shares).","Adjournment proposal also approved but not needed; meeting not adjourned."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-014601","json":"https://secwatch.observer/filing/0000950170-25-014601.json","markdown":"https://secwatch.observer/filing/0000950170-25-014601.md","text":"https://secwatch.observer/filing/0000950170-25-014601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025014601/0000950170-25-014601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025014601/tivc-20250131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:48:53.476520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}